{
    "clinical_study": {
        "@rank": "50215", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin B12 i.m.", 
                "arm_group_type": "Active Comparator", 
                "description": "Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks."
            }, 
            {
                "arm_group_label": "Vitamin B12 oral", 
                "arm_group_type": "Experimental", 
                "description": "High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring."
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, biomarker response after supplementation with oral and intramuscular vitamin\n      B12 will be compared in a randomized clinical trial. Electronic compliance monitoring will\n      be used to control for non compliance as a possible confounder in oral treatment.\n      Additionally subjective acceptance in terms of presumed preferences will be compared with\n      oral vs. intramuscular supplementation of vitamin B12 in the view of the patient."
        }, 
        "brief_title": "Vitamin B12 Acceptance and Biomarker Response Study", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitamin B 12 Deficiency", 
        "condition_browse": {
            "mesh_term": "Vitamin B 12 Deficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  General practitioner's prescription for Vitamin B12 deficiency testing\n\n          -  Age> 18 years\n\n          -  Ability to give written informed consent\n\n          -  Vitamin B12 serum concentrations < 200pmol/l\n\n          -  indication for vitamin B12 supplementation according to the General\n             practitioners estimation\n\n        Exclusion Criteria:\n\n          -  Patients with incorrect intake of vitamin preparations containing vitamin B12\n\n          -  Patients with previously diagnosed dementia\n\n          -  Patients with known hereditary transcobalamin transportation defects\n\n          -  lack of written and/or oral understanding in German, French, Italian or English\n             languages"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832129", 
            "org_study_id": "PCRG_VB12_CM"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin B12 oral", 
                "description": "Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.", 
                "intervention_name": "Oral administration of vitamin B12", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cyanocobolamin", 
                    "B12 \"Ankermann\" 1 mg"
                ]
            }, 
            {
                "arm_group_label": "Vitamin B12 i.m.", 
                "description": "Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.", 
                "intervention_name": "i.m. injection of vitamin B12", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vitamin B12 intramuscular", 
                    "Cyanocobolamin", 
                    "Vitarubin Depot"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin B 12", 
                "Hydroxocobalamin", 
                "Vitamin B Complex", 
                "Vitamins"
            ]
        }, 
        "lastchanged_date": "April 9, 2014", 
        "link": [
            {
                "description": "Pharmaceutical Care Research Group, University of Basel", 
                "url": "http://pharma.unibas.ch/research-groups/details/home/group/pharmaceuticalcare/"
            }, 
            {
                "description": "Study site", 
                "url": "http://www.aarelab.ch"
            }
        ], 
        "location": {
            "contact": {
                "email": "corina.metaxas@unibas.ch", 
                "last_name": "Corina Metaxas", 
                "phone": "+41 79 548 47 28"
            }, 
            "contact_backup": {
                "email": "philipp.walter@unibas.ch", 
                "last_name": "Philipp Walter"
            }, 
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "CH-4056"
                }, 
                "name": "Pharmaceutical Care Research Group"
            }, 
            "investigator": [
                {
                    "last_name": "Cyrill Jeger, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Philipp Walter, Msc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acceptance and Biomarker Response With Oral vs. Intramuscular Supplementation of Vitamin B12 in Primary Care", 
        "overall_contact": {
            "email": "corina.metaxas@unibas.ch", 
            "last_name": "Corina Metaxas"
        }, 
        "overall_contact_backup": {
            "email": "philipp.walter@unibas.ch", 
            "last_name": "Philipp Walter"
        }, 
        "overall_official": [
            {
                "affiliation": "Pharmaceutical Care Research Group", 
                "last_name": "Kurt E Hersberger, Professor", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Cyrill Jeger, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pharmaceutical Care Research Group", 
                "last_name": "Philipp N Walter, MSc", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vitamin B12 associated biomarkers (Vitamin B12, Holotranscobolamin, Homocystein, MCV, hypersegmentated neutrophils)", 
            "measure": "Biochemical response to vitamin B12 substitution", 
            "safety_issue": "No", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832129"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Basel", 
            "investigator_full_name": "Philipp Walter, PhD", 
            "investigator_title": "Msc", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Adherence to oral vitamin B12 supplementation will be measured with an electronic adherence monitoring device. The number of doses taken (taking adherence) and the number of doses taken within the defined time-frame (timing adherence) will be measured.", 
                "measure": "taking and timing adherence with oral vitamin B12", 
                "safety_issue": "No", 
                "time_frame": "day 28"
            }, 
            {
                "description": "Acceptance of the two routes of administration of vitamin B12 substitution by the patients will be measured by specific questionnaires before and after exposure to the medication in both arms.", 
                "measure": "Comparison of patient acceptance of oral vs. i.m. vitamin B12 supplementation", 
                "safety_issue": "No", 
                "time_frame": "day 0, day 28"
            }
        ], 
        "source": "University Hospital, Basel, Switzerland", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Pharmaceutical Care Research Group, University of Basel (Sponsor-Investigator)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Aarelab, Clinical Laboratory, Olten, Switzerland", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital, Basel, Switzerland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}